Drug Profile
Ceritinib companion diagnostic - Novartis
Alternative Names: LDK 378 companion diagnostic - NovartisLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Novartis
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in Japan
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in USA
- 08 Nov 2012 Clinical trials in Non-small cell lung cancer (diagnosis) in Japan (unspecified route)